cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.18133754
title: Supplementary Material for: Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial

description: <b><i>Introduction:</i></b> KidneyIntelX is a composite risk score, incorporating biomarkers and clinical variables for predicting progression of diabetic kidney disease (DKD). The utility of this score in the context of sodium glucose co-transporter 2 inhibitors and how changes in the risk score associate with future kidney outcomes are unknown. <b><i>Methods:</i></b> We measured soluble tumor necrosis factor receptor (TNFR)-1, soluble TNFR-2, and kidney injury molecule 1 on banked samples from CANagliflozin cardioVascular Assessment Study (CANVAS) trial participants with baseline DKD (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m<sup>2</sup> or urine albumin-to-creatinine ratio [UACR] ≥30 mg/g) and generated KidneyIntelX risk scores at baseline and years 1, 3, and 6. We assessed the association of baseline and changes in KidneyIntelX with subsequent DKD progression (composite outcome of an eGFR decline of ≥5 mL/min/year [using the 6-week eGFR as the baseline in the canagliflozin group], ≥40% sustained decline in the eGFR, or kidney failure). <b><i>Results:</i></b> We included 1,325 CANVAS participants with concurrent DKD and available baseline plasma samples (mean eGFR 65 mL/min/1.73 m<sup>2</sup> and median UACR 56 mg/g). During a mean follow-up of 5.6 years, 131 participants (9.9%) experienced the composite kidney outcome. Using risk cutoffs from prior validation studies, KidneyIntelX stratified patients to low- (42%), intermediate- (44%), and high-risk (15%) strata with cumulative incidence for the outcome of 3%, 11%, and 26% (risk ratio 8.4; 95% confidence interval [CI]: 5.0, 14.2) for the high-risk versus low-risk groups. The differences in eGFR slopes for canagliflozin versus placebo were 0.66, 1.52, and 2.16 mL/min/1.73 m<sup>2</sup> in low, intermediate, and high KidneyIntelX risk strata, respectively. KidneyIntelX risk scores declined by 5.4% (95% CI: −6.9, −3.9) in the canagliflozin arm at year 1 versus an increase of 6.3% (95% CI: 3.8, 8.7) in the placebo arm (<i>p</i> &lt; 0.001). Changes in the KidneyIntelX score at year 1 were associated with future risk of the composite outcome (odds ratio per 10 unit decrease 0.80; 95% CI: 0.77, 0.83; <i>p</i> &lt; 0.001) after accounting for the treatment arm, without evidence of effect modification by the baseline KidneyIntelX risk stratum or by the treatment arm. <b><i>Conclusions:</i></b> KidneyIntelX successfully risk-stratified a large multinational external cohort for progression of DKD, and greater numerical differences in the eGFR slope for canagliflozin versus placebo were observed in those with higher baseline KidneyIntelX scores. Canagliflozin treatment reduced KidneyIntelX risk scores over time and changes in the KidneyIntelX score from baseline to 1 year associated with future risk of DKD progression, independent of the baseline risk score and treatment arm.
DOI: 10.6084/m9.figshare.18133793
title: Supplementary Material for: Causes of Death in End-Stage Kidney Disease: Comparison between the United States Renal Data System and a Large Integrated Health Care System

description: <b><i>Introduction:</i></b> Using a large diverse population of incident end-stage kidney disease (ESKD) patients from an integrated health system, we sought to evaluate the concordance of causes of death (CODs) between the underlying COD from the United States Renal Data System (USRDS) registry and CODs obtained from Kaiser Permanente Southern California (KPSC). <b><i>Methods:</i></b> A retrospective cohort study was performed among incident ESKD patients who had mortality records and CODs reported in both KPSC and USRDS databases between January 1, 2007, and December 31, 2016. Underlying CODs reported by the KPSC were compared to the CODs reported by USRDS. Overall and subcategory-specific COD agreements were assessed using Cohen’s weighted kappa statistic (95% CI). Proportions of positive and negative agreement were also determined. <b><i>Results:</i></b> Among 4,188 ESKD patient deaths, 4,118 patients had CODs recorded in both KPSC and USRDS. The most common KPSC CODs were circulatory system diseases (35.7%), endocrine/nutritional/metabolic diseases (24.2%), genitourinary diseases (12.9%), and neoplasms (9.6%). Most common USRDS CODs were cardiac disease (46.9%), withdrawal from dialysis (12.6%), and infection (10.1%). Of 2,593 records with causes listed NOT as “Other,” 453 (17.4%) had no agreement in CODs between the USRDS and the underlying, secondary, tertiary, or quaternary causes recorded by KPSC. In comparing CODs recorded within KPSC to the USRDS, Cohen’s weighted kappa (95% CI) was 0.20 (0.18–0.22) with overall agreement of 36.4%. <b><i>Conclusion:</i></b> Among an incident ESKD population with mortality records, we found that there was only fair or slight agreement between CODs reported between the USRDS registry and KPSC, a large integrated health care system.
DOI: 10.6084/m9.figshare.18133793.v1
title: Supplementary Material for: Causes of Death in End-Stage Kidney Disease: Comparison between the United States Renal Data System and a Large Integrated Health Care System

description: <b><i>Introduction:</i></b> Using a large diverse population of incident end-stage kidney disease (ESKD) patients from an integrated health system, we sought to evaluate the concordance of causes of death (CODs) between the underlying COD from the United States Renal Data System (USRDS) registry and CODs obtained from Kaiser Permanente Southern California (KPSC). <b><i>Methods:</i></b> A retrospective cohort study was performed among incident ESKD patients who had mortality records and CODs reported in both KPSC and USRDS databases between January 1, 2007, and December 31, 2016. Underlying CODs reported by the KPSC were compared to the CODs reported by USRDS. Overall and subcategory-specific COD agreements were assessed using Cohen’s weighted kappa statistic (95% CI). Proportions of positive and negative agreement were also determined. <b><i>Results:</i></b> Among 4,188 ESKD patient deaths, 4,118 patients had CODs recorded in both KPSC and USRDS. The most common KPSC CODs were circulatory system diseases (35.7%), endocrine/nutritional/metabolic diseases (24.2%), genitourinary diseases (12.9%), and neoplasms (9.6%). Most common USRDS CODs were cardiac disease (46.9%), withdrawal from dialysis (12.6%), and infection (10.1%). Of 2,593 records with causes listed NOT as “Other,” 453 (17.4%) had no agreement in CODs between the USRDS and the underlying, secondary, tertiary, or quaternary causes recorded by KPSC. In comparing CODs recorded within KPSC to the USRDS, Cohen’s weighted kappa (95% CI) was 0.20 (0.18–0.22) with overall agreement of 36.4%. <b><i>Conclusion:</i></b> Among an incident ESKD population with mortality records, we found that there was only fair or slight agreement between CODs reported between the USRDS registry and KPSC, a large integrated health care system.
DOI: 10.17179/excli2021-4414/supplementary_tables
title: Preclinical safety profile of a liver-localized mitochondrial uncoupler: OPC-163493

description: Mitochondrial uncouplers (mUncouplers) are known to exhibit a variety of toxic effects in animals. Here we report a safety profile of an mUncoupler, OPC-163493, recently synthesized at Otsuka Pharmaceutical Co, Ltd, and its development as a therapeutic agent for treating diabetes. To understand the acute and subchronic toxicity of OPC-163493, single and repeated oral dose studies in rats, dogs, and monkeys were performed. In the rat studies, rigor mortis and increased body temperatures were observed in the high dose group. Focal necrosis, fatty change, and granular eosinophilic cytoplasm of the hepatocytes were also observed in the high dose group. In the dog studies, gastrointestinal manifestations were observed with decreased body weight and decreased food consumption in the high dose group. Necrotizing arteritis was observed in multiple organs as well as meningitis with hemorrhage in the brain. In the monkey studies, vomiting, decreased food consumption, and decreased locomotor activity were observed in the high dose group. Degeneration of the proximal convoluted tubules and the straight tubular epithelium, regeneration of the proximal tubular epithelium, and degeneration of the collecting tubular epithelium were observed. The target organs of OPC-163493 were liver, blood vessels, and kidney in rats, dogs, and monkeys, respectively. In rats, dogs, and monkeys, safety ratios were 100:1, 13:1, and 20:1, respectively, in terms of total exposure (AUC24h). These safety ratios showed clear separation between exposure to OPC-163493 in animals at NOAEL and the exposure at the effective dose in ZDF rats. This information should contribute to the drug development of new and effective mUncoupler candidates.
description: EXCLI Journal; 21:Doc213; ISSN 1611-2156
DOI: 10.48370/ofd/l56gp1
title: Pleospora penicillus Fuckel, 862

description: Fungarium Micromycetes
DOI: 10.48370/ofd/w4ftbb
title: Pleospora penicillus Fuckel, 1945

description: Fungarium Micromycetes
DOI: 10.48370/ofd/cdvbsr
title: Pleospora herbarum (Pers.) Rabenh., 3951

description: Fungarium Micromycetes
DOI: 10.17179/excli2021-4491/supplementary_data
title: Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: an in vitro study

description: The present study aimed to synthesize albendazole (ABZ)-loaded Mobil Composition of Matter No. 41 (MCM-41 NPs) to increase the efficacy of the drug against liver cancer. ABZ was loaded into MCM-41 NPs, and after in vitro characterization, such as size, size distribution, zeta potential, morphology, chemical composition, thermal profile, drug release, surface and pore volume, and pore size, their biological effects were evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) cell migration assays. The results demonstrated that monodispersed and spherical NPs with a size of 220 ± 11.5 and 293 ± 8.7 nm, for MCM-41 NPs and ABZ-loaded MCM-41 NPs, respectively, and drug loading efficiency of 30 % were synthesized. ABZ was loaded physically into MCM-41 NPs, leading to a decrease in surface volume, pore size, and pore volume. Also, MCM-41 NPs could increase the cytotoxicity effects of ABZ by 2.9-fold (IC50 = 23 and 7.9 µM for ABZ and ABZ-loaded MCM-41 NPs, respectively). In addition, both ABZ and ABZ-loaded MCM-41 NPs could restrain the cell migration by 12 %. Overall, the results of the present study suggest evaluating the potency of MCM-41 NPs, as a potent nanoplatform, for ABZ delivery in vivo environment.
description: EXCLI Journal; 21:Doc236; ISSN 1611-2156
DOI: 10.6084/m9.figshare.18133811
title: Supplementary Material for: Preliminary Clinical Validation of a Filtration-Based CTC Assay for Tumor Burden and HER2 Status Monitoring in Metastatic Breast Cancer

description: <b><i>Background:</i></b> Bearing multidimensional tumor-relevant information ranging from genomic alterations to proteomic makeup, circulating tumor cells (CTCs) constitute a promising material for liquid biopsy. The clinical validity of CTCs has been most extensively studied in metastatic breast cancer (MBC). The Cellsearch assay is currently the most widely used, while alternative strategies are pursued. A filtration-based microfluidic device has been described for CTC enrichment, but its clinical relevance remains unknown. <b><i>Methods:</i></b> In this preliminary study, we prospectively enrolled 47 MBC patients and evaluated the performance of the abovementioned CTC assay for tumor burden monitoring and human epidermal growth factor receptor 2 (HER2) status determination. <b><i>Results:</i></b> At baseline, 51.1% patients (24/47) were CTC positive. CTC count and positivity were also significantly higher in samples that accompanied poorer radiographic response evaluations. Serial blood draws suggested that CTC count enabled more accurate monitoring of tumor burden than serum markers carcinoembryonic antigen and cancer antigen 15-3. Also, in contrast to previous reports, CTC-HER2 status was moderately consistent with tumor-HER2 status. CTC-HER2 status assessment was further supported by <i>HER2</i> copy number measurements in select samples. <b><i>Conclusion:</i></b> The preliminary results from this study suggest promise for the interrogated CDC assay in several aspects, including sensitive CTC detection, accurate disease status reflection, and HER2 status determination. More studies are warranted to validate these findings and further characterize the value of CTC assay.
DOI: 10.6084/m9.figshare.18133811.v1
title: Supplementary Material for: Preliminary Clinical Validation of a Filtration-Based CTC Assay for Tumor Burden and HER2 Status Monitoring in Metastatic Breast Cancer

description: <b><i>Background:</i></b> Bearing multidimensional tumor-relevant information ranging from genomic alterations to proteomic makeup, circulating tumor cells (CTCs) constitute a promising material for liquid biopsy. The clinical validity of CTCs has been most extensively studied in metastatic breast cancer (MBC). The Cellsearch assay is currently the most widely used, while alternative strategies are pursued. A filtration-based microfluidic device has been described for CTC enrichment, but its clinical relevance remains unknown. <b><i>Methods:</i></b> In this preliminary study, we prospectively enrolled 47 MBC patients and evaluated the performance of the abovementioned CTC assay for tumor burden monitoring and human epidermal growth factor receptor 2 (HER2) status determination. <b><i>Results:</i></b> At baseline, 51.1% patients (24/47) were CTC positive. CTC count and positivity were also significantly higher in samples that accompanied poorer radiographic response evaluations. Serial blood draws suggested that CTC count enabled more accurate monitoring of tumor burden than serum markers carcinoembryonic antigen and cancer antigen 15-3. Also, in contrast to previous reports, CTC-HER2 status was moderately consistent with tumor-HER2 status. CTC-HER2 status assessment was further supported by <i>HER2</i> copy number measurements in select samples. <b><i>Conclusion:</i></b> The preliminary results from this study suggest promise for the interrogated CDC assay in several aspects, including sensitive CTC detection, accurate disease status reflection, and HER2 status determination. More studies are warranted to validate these findings and further characterize the value of CTC assay.
DOI: 10.48370/ofd/uxl8me
title: Pleospora penicillus Fuckel, 1311

description: Fungarium Micromycetes
DOI: 10.5281/zenodo.5835840
title: The Carbon Footprint of Astronomical Research Infrastructures

description: <strong>Content of the directory</strong> This record contains code and data that were used for the paper <strong>Knoedlseder, J., et al. Estimate of the carbon footprint of astronomical research infrastructures, Nature Astronomy, in press</strong>. <strong>Data</strong> The file <em>ri-carbon-footprint.xls</em> contains all data that were used for the analysis in the paper. The file is an excel file containing the following tabs: Description - a description of the excel file Summary - summary of the findings of the carbon footprint estimates Carbon footprint (ground) - Master table for carbon footprint of ground-based observatories Carbon footprint (space) - Master table for carbon footprint of space missions Emission factors - Collection of emission factors used as input to the study Active infrastructures - List of astronomical facilities that were active worldwide in 2019 Community - Astronomical community and IAU members for several countries (Ahn, S.H., Economic Power, Population, and Size of Astronomical Community, JKAS, 52, 159 (2019). <strong>Code</strong> The record contains three Python scripts. <strong><em>adsquery.py</em></strong> Script to query the ADS database to extract number of publications for a given facility. The script also determines the number of unique authors. It returns global numbers since the start of the mission or observatory operations, and numbers restricted to IRAP. <em><strong>bootstrap.py</strong></em> Script to bootstrap the considered facilities to extrapolate the carbon footprint to all infrastructures that exist worldwide. The script also produces Figure 1 of the paper. <strong><em>carbonintensity.py</em></strong> Script to generate various figures from the excel data, and in particular the carbon intensity Figure 2 of the paper. Running the script requires the "xlrd" Python module that can be installed via conda.
DOI: 10.5281/zenodo.5706331
title: The Carbon Footprint of Astronomical Research Infrastructures

description: <strong>Content of the directory</strong> This record contains code and data that were used for the paper <strong>Knoedlseder, J., et al. Estimate of the carbon footprint of astronomical research infrastructures, Nature Astronomy, in press</strong>. <strong>Data</strong> The file <em>ri-carbon-footprint.xls</em> contains all data that were used for the analysis in the paper. The file is an excel file containing the following tabs: Description - a description of the excel file Summary - summary of the findings of the carbon footprint estimates Carbon footprint (ground) - Master table for carbon footprint of ground-based observatories Carbon footprint (space) - Master table for carbon footprint of space missions Emission factors - Collection of emission factors used as input to the study Active infrastructures - List of astronomical facilities that were active worldwide in 2019 Community - Astronomical community and IAU members for several countries (Ahn, S.H., Economic Power, Population, and Size of Astronomical Community, JKAS, 52, 159 (2019). <strong>Code</strong> The record contains three Python scripts. <strong><em>adsquery.py</em></strong> Script to query the ADS database to extract number of publications for a given facility. The script also determines the number of unique authors. It returns global numbers since the start of the mission or observatory operations, and numbers restricted to IRAP. <em><strong>bootstrap.py</strong></em> Script to bootstrap the considered facilities to extrapolate the carbon footprint to all infrastructures that exist worldwide. The script also produces Figure 1 of the paper. <strong><em>carbonintensity.py</em></strong> Script to generate various figures from the excel data, and in particular the carbon intensity Figure 2 of the paper. Running the script requires the "xlrd" Python module that can be installed via conda.
DOI: 10.5517/ccdc.csd.cc1mcmj4
title: CCDC 1500726: Experimental Crystal Structure Determination

description: Related Article: R.Y. Morjan, S.M. El-Kurdi, J.N. Azarah, N.A. Eleiwa, O.S. Abu-Teim, A.M. Awadallah, J. Raftery, J.M. Gardiner|2018|Acta Crystallogr.,Sect.E:Cryst.Commun.|74|1362|doi:10.1107/S2056989018011222
DOI: 10.25505/fiz.icsd.cc20g3f1
title: CSD 1860602: Experimental Crystal Structure Determination

description: Related Article: Chunyan Jiang|2018|ICSD Communication|||
description: Related Article: Chunyan Jiang, Mingying Peng, Alok M. Srivastava, Lihua Li, Mikhail G. Brik|2018|Inorg.Chem.|57|14705|doi:10.1021/acs.inorgchem.8b02488
DOI: 10.5517/ccdc.csd.cc20gvcq
title: CCDC 1861313: Experimental Crystal Structure Determination

description: Related Article: R. Sribala, N. Srinivasan, S. Indumathi, R.V. Krishnakumar|2018|Acta Crystallogr.,Sect.E:Cryst.Commun.|74|1267|doi:10.1107/S2056989018011416
DOI: 10.5517/ccdc.csd.cc20gvdr
title: CCDC 1861314: Experimental Crystal Structure Determination

description: Related Article: R. Sribala, N. Srinivasan, S. Indumathi, R.V. Krishnakumar|2018|Acta Crystallogr.,Sect.E:Cryst.Commun.|74|1267|doi:10.1107/S2056989018011416
DOI: 10.25505/fiz.icsd.cc1zvwpd
title: CSD 1843095: Experimental Crystal Structure Determination

description: Related Article: Xiaofan Xu|2018|ICSD Communication|||
description: Related Article: Xiaofan Xu, Dandan Hu, Chaozhuang Xue, Jiaxu Zhang, Dong-Sheng Li, Tao Wu|2018|J.Mater.Chem.C|6|10480|doi:10.1039/C8TC03217C
DOI: 10.25505/fiz.icsd.cc20hy9s
title: CSD 1862365: Experimental Crystal Structure Determination

description: Related Article: Günther Thiele, Philipp Bron, Sina Lippert, Frederik Nietschke, Oliver Oeckler, Martin Koch, Bernhard Roling, Stefanie Dehnen|2019|Inorg.Chem.|58|4052|doi:10.1021/acs.inorgchem.8b02310
DOI: 10.25505/fiz.icsd.cc20j2n9
title: CSD 1862500: Experimental Crystal Structure Determination

description: Related Article: Alexandra A. Shmakova, Victoria V. Volchek, Vadim Yanshole, Nikolay B. Kompankov, Nicolas P. Martin, May Nyman, Pavel A. Abramov, Maxim N. Sokolov|2019|New J.Chem.|43|9943|doi:10.1039/C9NJ01907C
DOI: 10.5517/ccdc.csd.cc20jw3k
title: CCDC 1863258: Experimental Crystal Structure Determination

description: Related Article: K. Goleva, D. Naumova, A. Pavlishchuk, A.W. Addison, M. Zeller|2018|Acta Crystallogr.,Sect.E:Cryst.Commun.|74|1384|doi:10.1107/S2056989018012227
description: Related Article: J. Xu, R.W. Gable, C. Ritchie|2018|Acta Crystallogr.,Sect.C:Cryst.Struct.Chem.|74|1384|doi:10.1107/S205322961801183X
DOI: 10.5517/ccdc.csd.cc200k2p
title: CCDC 1847571: Experimental Crystal Structure Determination

description: Related Article: P.I. Nkoe, H.G. Visser, C. Swart, A. Brink, M. Schutte-Smith|2018|Acta Crystallogr.,Sect.C:Cryst.Struct.Chem.|74|1116|doi:10.1107/S205322961801207X
DOI: 10.5517/ccdc.csd.cc20knbl
title: CCDC 1864009: Experimental Crystal Structure Determination

description: Related Article: P.I. Nkoe, H.G. Visser, C. Swart, A. Brink, M. Schutte-Smith|2018|Acta Crystallogr.,Sect.C:Cryst.Struct.Chem.|74|1116|doi:10.1107/S205322961801207X
DOI: 10.5281/zenodo.5835738
title: Raw and analyzed data for manuscript "The synergistic effect of microwave drying and plasma surface treatments on the wettability of green wood"

description: <strong>Abstract:</strong> In spite of being a one-step solution to several problems associated with woodworking and being energy efficient, the application of microwave (MW) modification in wood research remained very limited and the promising method has practically no use in wood industries across the globe. Research done so far in this field primarily sheds light on its potential in enhancing wood permeability, treatability and uniform wood drying. While MW treatments are mostly used on wet or green wood, another modification technique, plasma, has potential benefits to synergistically enhance effects of MW treatment, but has not been applied on wet or green wood specimens, so far. This study takes a first step to investigate effects of plasma treatments (PT) on green wood specimens as well as combinations of MW and plasma treatments. As a preliminary study, the methodology focuses on water contact angle measurements, since these are most commonly used as indicators for surface modifications in industrial applications. On the investigated samples of Norway spruce (<em>Picea abies</em> Karst.), an exponential time dependence was found for the contact angle. Initial contact angle after droplet deposition increased due to drying and migration of organic molecules during treatments. In comparison to the literature, the effect of plasma was significantly less pronounced on wet wood specimens. The initial contact angle showed lowest statistical variations after MW treatment, whereas plasma increased inhomogeneities. The final contact angle on treated specimens was lowest for PT-only specimens as well as specimens treated with plasma after MW. In contrast to the initial contact angle, the final contact angle showed lowest variations after PT. Wetting rates were insignificantly improved by plasma, with reduced statistical variations after all treatments.
description: Accepted for publication in journal Les/Wood
DOI: 10.25505/fiz.icsd.cc20kpw5
title: CSD 1864057: Experimental Crystal Structure Determination

description: Related Article: José Barbosa, Carmelo Prestipino, Olivier J. Hernandez, Serge Paofai, Catherine Dejoie, Maryline Guilloux-Viry, Clotilde Boulanger|2019|Inorg.Chem.|58|2158|doi:10.1021/acs.inorgchem.8b03259